Graft Polymer (UK) - Notice of GM and proposed name change

Solvonis Therapeutics

03/12/2024 09:44

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241203:nRSC6053Oa&default-theme=true

RNS Number : 6053O  Graft Polymer (UK) PLC  03 December 2024

 

 

 03 December 2024

Graft Polymer (UK) Plc

(the "Company")

 

Proposed change of name to Solvonis Therapeutics Plc

 

Continuing progress with the Awakn collaboration

 

Proposed change of name

 

Graft Polymer (UK) Plc (LON:GPL) announces its intention to change its name to
Solvonis Therapeutics Plc, subject to approval of its shareholders at a
general meeting of the Company (the "GM"), to be held at  Eccleston Yards, 25
EP, Victoria, London, SW1W 9NF on 6 January, 2025 at 1:00pm GMT.  This
resolution will be proposed as a special resolution.

 

The proposed name, "Solvonis Therapeutics Plc" aligns more closely with the
Company's strategic focus on developing intellectual property and
co-developing therapeutics to address mental health and substance use
disorders.

 

"Solvonis" reflect the Company's mission to improve outcomes for individuals
and families affected by mental health and substance use disorders. The
Company's initial focus is on trauma-related mental health disorders, such as
post-traumatic stress disorder ("PTSD"). This mission will continue to be
executed through the Company's previously stated plan of joint ventures,
strategic partnerships, and mergers and acquisitions.

 

The proposed name change will be presented as a special resolution at the GM.
Details of the GM, including the time and venue, will be included in the
Notice of the General Meeting, which has been dispatched to shareholders today
and made available on the Company's website.

 

The Board of Directors unanimously supports the proposed name change,
believing it aligns with the Company's strategic objectives and serves the
best interests of the Company and its shareholders. The Board recommends that
shareholders vote in favour of the resolution to be proposed at the GM.

 

 

Continuing Progress with the Awakn Collaboration

 

The Company is pleased to report continued progress in its Aminoindane New
Chemical Entity (NCE) collaboration with Awakn, originally announced on 18
July 2024. This collaboration represents an important step in the Company's
efforts to advance innovative therapeutics for mental health. Results from the
initial studies, conducted in partnership with Eurofins Discovery and the
University of Nottingham, are expected to be reported imminently, marking a
key development in the programme.

 

Charnwood Discovery, Awakn's selected synthesis partner (announced on 28
August 2024), was acquired by Concept Life Sciences on 5 November 2024. Awakn
has confirmed that its collaboration will continue with Concept Life Sciences,
ensuring a smooth transition for any further synthesis activities required to
advance the Aminoindane NCE programme. These developments highlight the
continued momentum and focus on delivering progress within this promising area
of therapeutic research.

 

 

Enquiries:

 

Graft Polymer (UK) Plc

Anthony Tennyson, CEO and Executive Director.
anthonytennyson@graftpolymer.co.uk

 

Allenby Capital (Broker) +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

 

 

About Graft Polymer (UK) Plc

 

Graft Polymer (UK) Plc is an innovative biotechnology company focused on
developing intellectual property relating to the treatment of mental health
and substance use disorders, and the co-development of therapeutics for mental
health disorders.  Our mission is to improve outcomes for individuals
suffering from these conditions, with an initial focus on trauma-related
mental health disorders, such as PTSD, which affects approximately 13 million
adults in the U.S. and 20 million in US, UK, and key EU markets.

 

For more information, please visit www.graftpolymer.co.uk
(http://www.graftpolymer.co.uk) .

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOGKXLBBZLLZFBB